background
human
rhinovirus
hrv
respons
half
case
common
cold
caus
billion
usd
annual
medic
visit
school
work
absente
assess
made
cytotox
antivir
activ
possibl
mode
action
tannin
ellag
acid
leav
lagerstroemia
speciosa
toward
hela
cell
three
rhinovirus
antivir
properti
mechan
action
ellag
acid
evalu
use
sulforhodamin
b
assay
realtim
revers
transcriptionpcr
rtpcr
sybr
green
dye
result
compar
current
use
broadspectrum
antivir
agent
ribavirin
result
judg
inhibitori
concentr
valu
natur
ellag
acid
time
toxic
toward
ribavirin
respect
inhibit
rate
preincub
ellag
acid
wherea
continu
presenc
ellag
acid
infect
led
signific
increas
inhibit
treatment
ellag
acid
consider
suppress
infect
ad
viru
inocul
h
inhibit
h
h
later
inhibit
find
suggest
ellag
acid
interact
particl
may
directli
interact
human
cell
earli
stage
hrv
infect
protect
cell
viru
destruct
furthermor
rtpcr
analysi
reveal
ellag
acid
strongli
inhibit
rna
replic
hela
cell
suggest
ellag
acid
inhibit
viru
replic
target
cellular
molecul
rather
viru
molecul
conclus
global
effort
reduc
level
antibiot
justifi
studi
l
speciosa
leafderiv
materi
contain
ellag
acid
potenti
antihrv
product
lead
molecul
prevent
treatment
hrv
infect
human
rhinovirus
hrv
picornavirida
frequent
caus
mild
upper
respiratori
tract
infect
common
cold
respons
half
case
common
cold
hrv
also
associ
sever
diseas
acut
otiti
media
children
sinus
adult
hrv
also
caus
sever
lower
respiratori
tract
infect
pneumonia
wheez
bronchiol
exacerb
asthma
chronic
obstruct
pulmonari
diseas
infant
children
well
fatal
pneumonia
elderli
immunocompromis
adult
although
hrvinduc
upper
respiratori
ill
often
mild
selflimit
socioeconom
impact
caus
medic
visit
school
work
absente
hrv
infect
consider
degre
inappropri
antibiot
use
signific
serotyp
hrv
becom
obstacl
develop
unifi
vaccin
therefor
high
need
develop
select
antivir
agent
novel
target
site
establish
effect
hrv
manag
strategi
tactic
current
approv
antivir
therapi
prevent
treatment
hrv
infect
plant
suggest
altern
sourc
antivir
product
larg
constitut
potenti
sourc
bioactiv
secondari
substanc
perceiv
gener
public
rel
safe
minim
impact
human
health
often
act
multipl
novel
target
site
much
effort
focus
plant
constitu
potenti
sourc
commerci
antivir
product
prevent
treatment
hrv
infect
screen
plant
antihrv
activ
methanol
extract
leav
giant
crapemyrtl
call
banaba
phillippin
lagerstroemia
speciosa
l
per
lythracea
shown
good
antivir
activ
toward
littl
inform
done
consid
potenti
use
l
speciosa
manag
hrv
although
plant
leav
possess
antidiabet
hypoglycem
antiobes
antioxid
antigout
antiinflammatori
antibacteri
activ
aim
studi
assess
cytotox
antivir
effect
hela
cell
three
hrv
serotyp
tannin
ellag
acid
l
speciosa
leav
compar
commerci
pure
ellag
acid
ribavirin
current
use
broadspectrum
antivir
agent
antivir
properti
mechan
action
constitu
elucid
use
sulforhodamin
b
srb
assay
realtim
revers
transcriptionpcr
sybr
green
dye
h
c
nmr
spectra
record
dmsod
jnmecx
spectromet
jeol
tokyo
japan
mhz
respect
use
tetramethylsilan
intern
standard
chemic
shift
given
ppm
uv
spectra
obtain
methanol
biomat
spectrophotomet
thermo
spectron
rochest
ny
fourier
transform
infrar
ftir
spectra
nicolet
magna
seri
ii
spectromet
midac
atlanta
ga
mass
spectra
jeol
gsx
spectromet
silica
gel
mm
merck
darmstadt
germani
use
column
chromatographi
merck
precoat
silica
gel
plate
kieselgel
f
mm
use
analyt
thinlay
chromatographi
tlc
avp
highperform
liquid
chromatograph
shimadzu
kyoto
japan
use
isol
activ
principl
commerci
avail
pure
ellag
acid
puriti
srb
purchas
sigmaaldrich
st
loui
mo
antivir
agent
ribavirin
suppli
tokyo
chemic
industri
tokyo
anitbioticantimycot
minimum
essenti
medium
mem
purchas
invitrogen
grand
island
ny
fetal
bovin
serum
suppli
paa
laboratori
etobicok
ontario
canada
chemic
reagent
use
studi
analyt
grade
qualiti
avail
commerci
hela
atcc
human
epitheli
adenocarcinoma
cervix
cell
line
purchas
american
type
cultur
collect
atcc
manassa
va
cell
line
maintain
mem
supplement
fetal
bovin
serum
antibioticantimycot
humidifi
incub
co
atcc
atcc
atcc
purchas
atcc
three
hrv
propag
hela
cell
viru
titer
determin
cytopath
effect
cpe
hela
cell
express
cell
cultur
infect
dose
ccid
per
ml
describ
previous
airdri
leav
l
speciosa
purchas
local
giant
crapemyrtl
farm
philippin
certifi
botan
taxonomist
use
identifi
plant
voucher
specimen
l
deposit
research
institut
agricultur
life
scienc
colleg
agricultur
life
scienc
seoul
nation
univers
airdri
leav
kg
l
speciosa
pulver
extract
methanol
l
room
temperatur
day
filter
combin
filtrat
concentr
dryness
rotari
evapor
yield
g
dark
greenish
powder
extract
g
sequenti
partit
hexan
g
ethyl
acet
g
butanol
g
watersolubl
g
portion
subsequ
bioassay
organ
solventsolubl
portion
concentr
vacuum
watersolubl
portion
concentr
isol
activ
principl
viral
cpe
inhibit
assay
describ
previous
toward
hela
cell
use
ethyl
acetatesolubl
fraction
g
biolog
activ
tabl
give
activ
fraction
mg
r
f
separ
constitu
activ
fraction
highperform
liquid
chromatographi
perform
column
mm
id
mm
ec
nucleodex
alphapm
machereynagel
easton
pa
use
mobil
phase
methanol
water
volum
flow
rate
mlmin
chromatograph
separ
monitor
use
uv
detector
nm
final
activ
principl
mg
isol
retent
time
min
isol
obtain
green
amorph
powder
identifi
instrument
analys
includ
ms
nmr
mass
spectrum
exhibit
molecular
ion
mz
ir
absorpt
cm
indic
presenc
phenol
hydroxyl
c
benzonoid
c
c
group
respect
compound
thu
identifi
ellag
acid
figur
interpret
proton
carbon
signal
larg
consist
nawwar
souleman
ellag
acid
identifi
basi
follow
evid
green
amorph
power
uv
meoh
max
nm
ftir
max
cm
eim
ev
antivir
activ
l
speciosa
leafderiv
materi
toward
three
hrv
test
evalu
srb
method
use
cpe
reduct
brief
hela
cell
seed
onto
microtit
plate
concentr
cell
per
well
day
od
tv
od
cv
od
cd
od
cv
od
tv
optic
densiti
measur
given
concentr
test
materi
hrv
infect
cell
od
cv
optic
densiti
measur
control
untreat
hrv
infect
cell
od
cd
optic
densiti
measur
control
untreat
hrv
uninfect
cell
hela
cell
seed
onto
microtit
plate
state
previous
cultur
medium
remov
plate
replac
media
contain
differ
concentr
test
materi
dmso
base
preliminari
test
result
incub
co
day
cytotox
test
materi
hela
cell
evalu
use
srb
assay
state
previous
effect
ellag
acid
ribavirin
infect
particl
evalu
describ
previous
choi
et
al
approxim
twofold
quantiti
ic
valu
test
compound
appli
preincub
ellag
acid
ribavirin
h
monolay
hela
cell
infect
pretreat
untreat
h
unbound
viru
remov
wash
well
pb
cell
incub
fresh
medium
supplement
without
test
compound
day
srb
test
antivir
activ
carri
state
previous
timeofaddit
effect
ellag
acid
test
accord
method
choi
et
al
brief
monolay
hela
cell
seed
onto
microtit
plate
state
previous
wash
pb
ellag
acid
ad
onto
cultur
cell
h
h
h
infect
ribavirin
serv
posit
control
similarli
prepar
day
srb
test
antivir
activ
carri
state
previous
evalu
level
gene
express
quantit
realtim
revers
transcriptionpcr
rtpcr
sybr
green
dye
perform
infect
noninfect
cultur
hela
cell
grown
corn
cm
cell
cultur
flask
corn
ny
treat
cytotox
express
cytotox
concentr
cc
compound
reduc
viabil
cell
control
fifti
percent
inhibitori
concentr
ic
defin
compound
concentr
requir
reduc
viral
cpe
control
cc
ic
valu
calcul
use
graphpad
prism
softwar
graphpad
softwar
la
jolla
ca
therapeut
index
determin
ratio
cc
ic
result
express
mean
sd
triplic
sampl
three
independ
experi
statist
analys
carri
use
sa
program
sa
institut
cari
nc
data
two
group
analyz
student
ttest
multipl
group
analyz
oneway
analysi
varianc
bonferroni
multipl
comparison
test
antivir
activ
natur
ellag
acid
commerci
pure
ellag
acid
ribavirin
significantli
differ
toward
f
df
p
f
df
p
f
df
p
tabl
base
ic
valu
natur
ellag
acid
pure
ellag
acid
differ
significantli
antivir
activ
toward
three
hrv
indic
activ
methanolextract
ellag
acid
pure
due
ellag
acid
natur
ellag
acid
time
toxic
toward
ic
ribavirin
respect
cc
ellag
acid
ribavirin
toward
hela
cell
srb
assay
effect
ellag
acid
ribavirin
infect
particl
likewis
examin
figur
inhibit
rate
preincub
ellag
acid
ribavirin
respect
continu
presenc
ellag
acid
ribavirin
infect
led
signific
increas
inhibit
rate
investig
mode
action
ellag
acid
ribavirin
time
cours
inhibit
compound
differ
period
infect
likewis
investig
figur
treatment
ellag
acid
consider
suppress
hrv
infect
ad
viru
inocul
h
inhibit
inhibit
rate
ellag
acid
declin
less
ad
either
prior
h
post
h
infect
howev
inhibitori
effect
ribavirin
infect
occur
h
rna
replic
level
hela
cell
remark
inhibit
cell
cultur
treat
ellag
acid
figur
rna
replic
level
reduc
fold
compar
level
cell
cultur
without
ellag
acid
current
vitro
studi
indic
materi
deriv
l
speciosa
leav
exhibit
antivir
activ
select
toward
three
rhinovirus
plant
grow
wide
tropic
countri
includ
philippin
india
malaysia
china
australia
popular
folk
medicin
southeast
asia
l
speciosa
leav
contain
acet
alkaloid
sterol
tannin
triterpenoid
excel
antidiabet
properti
standard
extract
l
speciosa
leav
well
note
variou
compound
includ
phenol
terpenoid
alkaloid
exist
plant
jointli
independ
contribut
antivir
efficaci
mani
plant
constitu
manifest
antivir
activ
toward
differ
virus
propos
altern
convent
antivir
drug
antihrv
organ
acid
eg
raoulic
acid
ic
gallic
acid
ic
thiosulfin
allicin
allyl
methylthiosulfin
report
hrv
capsidbind
compound
toward
hrv
serotyp
show
exist
group
b
base
wide
rang
suscept
antivir
compound
current
studi
antivir
principl
determin
tannin
ellag
acid
constitu
exhibit
antivir
activ
toward
group
group
b
ic
ellag
acid
toward
three
hrv
although
ic
natur
compound
state
previous
ellag
acid
exhibit
greater
antivir
activ
ribavirin
toward
three
hrv
high
select
origin
find
indic
materi
deriv
l
speciosa
leav
hold
promis
develop
novel
effect
natur
occur
antivir
agent
two
differ
hrv
group
b
addit
ellag
acid
report
possess
antihiv
activ
inhibit
hiv
proteas
orobol
l
speciosa
leav
also
known
broadspectrum
antivir
activ
toward
variou
hrv
includ
group
b
well
pleconarilresist
investig
mode
antivir
action
natur
occur
compound
may
contribut
develop
select
hrv
therapeut
altern
novel
target
site
mode
antihrv
action
plant
secondari
substanc
well
review
rolling
schmidtk
target
viru
molecul
like
specif
less
toxic
narrow
spectrum
virus
higher
risk
creat
resist
virus
contrari
chemic
target
cellular
molecul
may
possess
broader
antivir
activ
spectrum
less
risk
develop
viru
resist
may
toxic
host
cell
current
studi
ellag
acid
interact
particl
preexposur
viru
constitu
alter
infect
particl
base
timeofaddit
experi
ellag
acid
significantli
suppress
infect
ad
viru
inocul
h
h
h
later
find
suggest
ellag
acid
may
directli
interact
human
cell
earli
stage
hrv
infect
protect
cell
viru
destruct
addit
rtpcr
analysi
reveal
ellag
acid
strongli
inhibit
rna
replic
hela
system
suggest
ellag
acid
inhibit
viru
replic
target
cellular
molecul
rather
viru
molecul
detail
test
need
fulli
understand
antihrv
mode
action
ellag
acid
l
speciosa
leafderiv
prepar
contain
ellag
acid
could
use
antivir
agent
prevent
treatment
hrv
infect
antivir
action
ellag
acid
may
indic
least
one
pharmacolog
action
l
speciosa
practic
use
l
speciosa
leafderiv
prepar
novel
antihrv
product
proceed
research
need
establish
human
safeti
whether
activ
exert
vivo
consumpt
l
speciosa
leafderiv
product
human
histor
tea
plant
leav
use
treatment
diabet
mellitu
philippin
rat
fed
ellag
acid
dose
high
mgday
day
caus
sign
system
toxic
lastli
detail
test
need
understand
improv
antihrv
potenc
stabil
eventu
commerci
develop
softwar
bar
repres
mean
sd
duplic
sampl
three
independ
experi
signific
p
accord
student
ttest
